Clinical Trials Browser

Phase 2 × Lymphoma, Large B-Cell, Diffuse × pembrolizumab × Clear all

NCT06863402 2026-05-20

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02362997 2026-05-18

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Phase 2 Completed

82 enrolled 20 charts

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT05221645 2026-05-15

P+R-ICE

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03349450 2026-05-06

SPiReL

Phase 2 Completed

25 enrolled 18 charts

LymphoidSarcoma

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT05507541 2026-04-22

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02446457 2026-03-09

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Phase 2 Active not recruiting

53 enrolled 10 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT03990961 2026-02-20

Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)

Phase 2 Terminated

5 enrolled 11 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05179603 2025-12-24

A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]

Phase 2 Terminated

14 enrolled 15 charts

Lymphoma, Large B-Cell, Diffuse

NCT03401853 2025-07-22

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Phase 2 Terminated

18 enrolled 14 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03995147 2025-06-08

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03255018 2023-11-28

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Phase 2 Completed

12 enrolled 21 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04920617 2023-04-07

VITALIZE

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse